EMA: Diabetes drugs with glargine do not raise cancer risk

06/3/2013 | Medscape (free registration)

Diabetes drugs containing insulin glargine do not appear to increase the risk of cancer in patients, the European Medicines Agency's Committee for Medicinal Products for Human Use concluded. The committee reviewed two new cohort studies as well as studies from a search of the scientific literature.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Systems Test - V&V Engineer - 14000008LS
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC